Health Policy

The European Medicines Agency’s Management Board met in Amsterdam on 10 and 11 June 2026. The European Commission reported that the first EU joint clinical assessment report appeared on 9 June 2026. Since the Health Technology Assessment Regulation took effect in January 2025, 18 JCAs have started. Seven Joint Scientific Consultations have finished under the Regulation, and the first JCAs for medical devices and in vitro diagnostics will begin in June 2026. Initiative Status Timing First EU joint clinical assessment […]

South Africa's drugmakers and the health department are at odds over lowest-price tenders. Pharmisa says cheaper imports have cost more than 2,500 jobs and eroded local manufacturing capacity.

The NICE Decision Support Unit and EEPRU have released updated Stata, Excel and R commands for mapping EQ-5D-3L data to the new EQ-5D-5L value set, giving UK HTA analysts a validated route to convert legacy three-level utility data ahead of NICE's adoption of the five-level value set.

How are cell therapies redefining cancer care through rigorous HTA evaluation? INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness. Explore the full breakdown and its implications for global cancer treatment. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

Is the US childhood vaccine schedule really out of step with peer nations? A new analysis finds it aligns closely with other developed countries in both the number and timing of recommended vaccines. Explore the full comparison and what it means for vaccine policy. #SyenzaNews #globalhealth #HealthcareInnovation #healthcarepolicy #innovation

❓ How is Portugal’s approval of ublituximab reshaping access to multiple sclerosis therapies? The decision introduces new restrictions that could limit patient options and complicate market entry for innovative MS treatments. Explore the full implications for healthcare access and regulatory strategy. #SyenzaNews #pharmaceuticals #HealthcareInnovation #MarketAccess #healthcarepolicy

Is the PRIME scheme growing more exclusive for innovative medicines? Eligibility criteria for the European Medicines Agency’s PRIME scheme remain highly selective in 2026, underscoring the rigorous standards required to secure early regulatory support for therapies addressing unmet medical needs. Discover what this means for drug developers and patients. #SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #MarketAccess

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

🚀 How is the India-SACU trade agreement unlocking new pharma growth? This landmark deal is expanding market access, cutting tariffs, and accelerating exports for Indian pharmaceutical companies across Southern Africa. Discover the strategic opportunities it creates for the sector. #SyenzaNews #pharmaceuticals #globalhealth #innovation #MarketAccess

Can local procurement policies turn the tide for South Africa’s pharmaceutical jobs? A strategic shift toward prioritizing local pharma manufacturing could safeguard thousands of positions while strengthening supply chain resilience and economic growth. This approach balances cost considerations with long-term industrial development in the sector. Explore the full analysis. #SyenzaNews #pharmaceuticals #MarketAccess #healthcarepolicy

📈 How is the GLP-1 surge reshaping pharmaceutical forecasts? Novo Nordisk has raised its full-year profit guidance, propelled by explosive demand for its GLP-1 therapies in diabetes and obesity care. Discover the market forces behind this momentum. #SyenzaNews #pharmaceuticals #biotech #innovation #MarketAccess

⚠️ What breaches were uncovered in a Portuguese surgeon’s disciplinary review? A recent investigation has exposed serious lapses in clinical standards and regulatory compliance, raising fresh questions about accountability in surgical practice. Read the full analysis to see what this means for patient safety and oversight. #SyenzaNews #regulatoryaffairs #HealthcareInnovation #governance #innovation